Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

Recruiting NCT03301038

Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria

Conditions: Idiopathic Infantile Hypercalcaemia - Severe Form, Genetic Disease, Hypercalcemia, Idiopathic, of Infancy, Hypercalciuric Hypercalcemia, Idiopathic Infantile Hypercalcemia - Mild Form, Hypercalciuria

Sex: All

Ages: 6 Months – 65 Years

Healthy volunteers: No

Phase: PHASE2

Enrollment: 60

Sponsor: Children's Hospital of Philadelphia

Location: Children's Hospital of Philadelphia Philadelphia Pennsylvania

Summary

This study evaluates the efficacy of rifampin in the treatment of hypercalcemia and/or hypercalciuria in participants with at least one inactivating mutation of the CYP24A1 gene. Eligible subjects will receive rifampin for a total of 16 weeks during this study.

Eligibility Criteria

Inclusion Criteria: * Males or females age 6 months to 65 years. * at least one mutations of CYP24A1 * Serum and/or urinary calcium above the normal reference range for age * Serum PTH concentration \ 2.0 times the upper limit of normal Alanine aminotransferase (ALT/SGPT) \> 2.0 times the upper limit of normal Total bilirubin \> 2.0 times the upper limit of normal Creatinine \> 2.0 times the upper limit of normal

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT03301038). StuddyBuddy aggregates publicly available trial information.